Work

73P Cognitive toxicity of avapritinib: A case series

Year: 2025

Type: article

Abstract: Avapritinib is a KIT and PDGFRA inhibitor with high potency against KIT D816V and PDGFRA D842V mutations, and is used primarily in advanced GIST with PDGFRA D842V mutation. In the landmark phase III VOYAGER trial, cognitive events of any grade were reported in 26% of patients treated with avapritinib (grade 3: 1.3%). It is hypothesised that inhibition of PDGFRβ may lead to disruption of the blood-brain barrier and accumulation of neurotoxic proteins.

Source: ESMO Open

DOI: 10.1016/j.esmoop.2025.104387

Authors: A. De Bernardi, E. Turcotte

Language: English

Topic: Gastrointestinal Tumor Research and Treatment

Subfield: Gastroenterology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,910

OpenAlex ID: W4408747994

FWCI:

Cites:

Cited by:

Related to: 10